Hepatotoxicity and ADME services
Why us
Our NANOSTACKSTM-based in vitro models recapitulate the cell-cell crosstalk, fluid flow and spatial cellular arrangement typical of the in vivo environment. This way, toxicity screening on our models can yield more accurate results than the use of traditional models. We provide in vitro testing services using the in vitro model of your choice.
Why choose our NANOSTACKSTM liver models
Superior performance compared to other hepatic models
Click on the options below to explore our validated solutions for hepatotoxicity and ADME studies
The model is built using our proprietary NANOSTACKS™ technology
- Layer 1: Hepatocytes compartment
- Cell type: Primary human hepatocytes
- Primary human hepatocytes (PHH) are the gold standard for hepatotoxicity screening due to their physiological relevance and ability to recapitulate key liver functions, such as CYP activity and albumin production. The model can be utilized in various ways, including as a standalone model or as a control for our triculture and tetraculture models.
- Fluid flow included
OUTPUTS
Contact us for alternative endpoints.
Comprehensively validated liver monoculture model
PHH monoculture model DILI screening standard process & timeline*
*Dosing intervals and duration can be adjusted based on your requirements
Publication
Multicellular, fluid flow-inclusive hepatic in vitro models using NANOSTACKS™: a human-relevant model for drug response prediction
Talari et al, 2024
Drug-induced liver injury (DILI) is a leading cause of drug failure in clinical trials and post-market withdrawals, largely due to the limitations of current preclinical models. This study introduces the NANOSTACKS™ platform as a novel in vitro tool to create in vivo-like liver models for predicting drug responses. We developed and characterized hepatic models—monocultures of primary human hepatocytes (PHH), tricultures with PHH, stellate cells (HSC), and liver endothelial cells (LECs), and tetracultures adding Kupffer cells (KC)—under static and fluid flow conditions. These models were evaluated for albumin, urea, CYP3A4, and ATP production. The fluid flow-inclusive models were further tested for DILI screening using Zileuton, Buspirone, and Cyclophosphamide, demonstrating the potential of NANOSTACKS™ for developing advanced in vitro models.
PUBLICATIONUnique Benefits
Get in Touch
Explore how our models support your research studies
Alternative solutions
Need some help?
If you're interested in discovering how our organ models can benefit your research, we invite you to get in touch with us. Our team is available to provide further insights and address any inquiries you may have.